Evidence literacy
Translational research: how findings move between models and human questions
Translational research connects basic mechanisms, preclinical models, human studies, implementation, and population outcomes. The process is iterative and can fail at multiple points, so a promising early result should retain its evidence stage.
Educational content only. Not medical advice.
Translation is a network, not a one-way pipeline
Basic findings can motivate preclinical models, human observations can reshape laboratory questions, and implementation can reveal gaps that return research to earlier stages. The NCATS spectrum emphasizes that translation is not strictly linear. A molecule can have a coherent mechanism while development pauses because exposure, measurement, safety, manufacturing, or clinical relevance remains unresolved.
Model validity has several dimensions
A model may resemble visible features of a condition, share a causal mechanism, or predict response to known interventions. These forms of validity are related but not identical. An experimentally convenient injury or genetically uniform animal can clarify one pathway while failing to represent the heterogeneity, time course, comorbidities, or environment of human disease.
Exposure and measurement must also translate
Similar nominal concentration does not guarantee similar target-site exposure across cells, tissues, species, or formulations. Assays may detect parent material, metabolites, or cross-reactive signals differently. Translational reasoning therefore includes identity, stability, PK, target engagement, validated biomarkers, and outcome relevance. A favorable result in one model is not enough.
State the exact rung the evidence reaches
A careful summary says whether evidence is biochemical, cellular, ex vivo, animal, observational human, early interventional, confirmatory, implementation, or population-level. It then names the unresolved bridge. Phrases such as may inform or supports further study are appropriate when translation is incomplete; claims of human benefit require direct human outcome evidence.
Evidence limits
- The translational spectrum simplifies programs that can branch, stop, or move backward.
- No model can reproduce every feature of a heterogeneous human condition.
- Mechanistic plausibility and target engagement do not establish patient-relevant benefit.
Sources and further reading
These sources ground the definitions and evidence boundaries on this page. A citation is a route for verification, not an endorsement of a product or personal use.
National Center for Advancing Translational Sciences
Translational Science Spectrum
Official map of basic, preclinical, clinical, implementation, and public-health translation stages.
Open sourceNational Institutes of Health
Enhancing Reproducibility through Rigor and Transparency
Official NIH principles for rigorous design, authentication, transparency, and reproducible biomedical research.
Open sourceNational Cancer Institute
Definition of In Vivo
Official NCI definition of processes or experiments within a living organism.
Open sourceCommon questions
What does bench to bedside mean?
It is shorthand for moving laboratory insights toward human research and care, but real translation is iterative and multidirectional.
Why do positive animal studies fail in humans?
Possible reasons include model mismatch, exposure differences, bias, measurement limits, safety, and heterogeneous human biology.
Does early human target engagement prove efficacy?
No. It shows a biological step occurred; patient-relevant outcomes require separately designed evidence.
Continue with context
Keep building your evidence-reading skills
Explore the public PeptideSchool research library for more source-backed methods, glossaries, and evidence maps.